USPTO serial 99693310
NANOSYRINGE
Reviewed by CopyMark Law Group
Status 681
- Filing date
- Status date
- Registration date
- Nov 10, 2026
- Examiner
- HAYES, GINA CLARK
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with NANOSYRINGE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
West Midlands, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jordan Arnot Leahey
Jordan Arnot Leahey CM LAW PLLC13101 Preston Road Ste 110-1520Dallas, TX 75240United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | cultures of micro-organisms, other than for medical and veterinary use, namely, for the targeted intracellular delivery of biological molecules; Chemical substances for analyses in laboratories, for use in science, industry, and for in vitro use for the targeted intracellular delivery of biological molecules; cell culture media for scientific and research purposes, namely, use in cell cultures for the targeted intracellular delivery of biological molecules; cell culture media for use in the biotechnological industry, other than for medical or veterinary purposes; nutritive substances for microorganism cultures, other than for medical or veterinary purposes, namely, for processing living cells for the targeted intracellular delivery of biological molecules; Active chemical ingredients and unprocessed polymers for use in the manufacture, development and testing of pharmaceuticals for the targeted intracellular delivery of biological molecules and for analysis in laboratories; proteins in raw material form for scientific research; peptide substrates for scientific purposes; protein in raw material form for scientific and medical research in the intracellular delivery of biological molecules; diagnostic reagents for scientific use for the targeted intracellular delivery of biological molecules, peptides, proteins, enzymes, gene editing enzymes, antibodies or antibody fragments; genetically-encoded protein complexes and protein assemblies, supplied in raw material form, supplied in an intermediate semi-processed form, or supplied in conjunction with buffer solutions or reagents, capable of binding to cell-surface antigens, for delivering biological molecules to target cells, for the purposes of scientific and medical research | ACTIVE | — |
| 005 | Pharmaceutical preparations for the targeted intracellular delivery of biological molecules, drugs, and therapeutic substances, namely, those containing peptides, proteins, enzymes, gene editing enzymes, antibodies, antibody fragments and genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, vaccines, and those for the treatment and prevention of metabolic diseases, diabetes, obesity, dyslipidemia, fibrotic diseases, liver disease, lung disease, kidney fibrosis, rare diseases, orphan diseases, cancer, genetic diseases, autoimmune diseases, neurological diseases, infectious diseases, cardiovascular diseases, neoplastic diseases, respiratory diseases, endocrine diseases, inflammatory diseases, musculoskeletal disorders, gastrointestinal and hepatic diseases, renal and urological diseases, reproductive diseases, gynecological disorders, dermatological diseases, ophthalmic diseases, hematological disorders, or diseases affecting the organs; Pharmaceutical and veterinary preparations for use in connection with intracellular delivery of drugs, antibodies and antibody fragments, enzymes, nucleic acids, proteins, peptides, small molecules, therapeutic substances focused on non-viral delivery technology for the treatment and prevention of metabolic diseases, diabetes, obesity, dyslipidemia, fibrotic diseases, liver disease, lung disease, kidney fibrosis, rare diseases, orphan diseases, cancer, genetic diseases, autoimmune diseases, neurological diseases, infectious diseases, cardiovascular diseases, neoplastic diseases, respiratory diseases, endocrine diseases, inflammatory diseases, musculoskeletal disorders, gastrointestinal and hepatic diseases, renal and urological diseases, reproductive diseases, gynecological disorders, dermatological diseases, ophthalmic diseases, hematological disorders, or diseases affecting the organs; Pharmaceutical preparations for gene editing for the treatment and prevention of metabolic diseases, diabetes, obesity, dyslipidemia, fibrotic diseases, liver disease, lung disease, kidney fibrosis, rare diseases, orphan diseases, cancer, genetic diseases, autoimmune diseases, neurological diseases, infectious diseases, cardiovascular diseases, neoplastic diseases, respiratory diseases, endocrine diseases, inflammatory diseases, musculoskeletal disorders, gastrointestinal and hepatic diseases, renal and urological diseases, reproductive diseases, gynecological disorders, dermatological diseases, ophthalmic diseases, hematological disorders, or diseases affecting the organs; pharmaceutical preparations for intracellular delivery of drugs, nucleic acids, proteins, peptides, therapeutic substances focused on the development of RNA therapies, therapeutic substances focused on non-viral delivery technology for the treatment and prevention of metabolic diseases, diabetes, obesity, dyslipidemia, fibrotic diseases, liver disease, lung disease, kidney fibrosis, rare diseases, orphan diseases, cancer, genetic diseases, autoimmune diseases, neurological diseases, infectious diseases, cardiovascular diseases, neoplastic diseases, respiratory diseases, endocrine diseases, inflammatory diseases, musculoskeletal disorders, gastrointestinal and hepatic diseases, renal and urological diseases, reproductive diseases, gynecological disorders, dermatological diseases, ophthalmic diseases, hematological disorders, or diseases affecting the organs; drug delivery agents in the form of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, that facilitate the delivery of pharmaceutical preparations for the targeted intracellular delivery of biological molecules, drugs, therapeutics, and pharmaceutical preparations, and for delivering pharmaceuticals to target cells; biologics in the nature of pharmaceutical preparations in the nature of intracellular delivery of biological molecules, drugs and therapeutics for the treatment and prevention of metabolic diseases, diabetes, obesity, dyslipidemia, fibrotic diseases, liver disease, lung disease, kidney fibrosis, rare diseases, orphan diseases, cancer, genetic diseases, autoimmune diseases, neurological diseases, infectious diseases, cardiovascular diseases, neoplastic diseases, respiratory diseases, endocrine diseases, inflammatory diseases, musculoskeletal disorders, gastrointestinal and hepatic diseases, renal and urological diseases, reproductive diseases, gynecological disorders, dermatological diseases, ophthalmic diseases, hematological disorders, or diseases affecting the organs; Drug delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceuticals, proteins and peptides to target cells; bacterial preparations for pharmaceutical and medical purposes for the targeted intracellular delivery of biological molecules, drugs and therapeutics; cultures of micro-organisms for medical and veterinary use; cell culture media for medical purposes, namely for the storage of micro-organisms, bacteria, and bacteriological cultures; nutritive substances for micro-organisms for medical purposes; bacterial and bacteriological preparations for veterinary use; pharmaceutical and veterinary preparations targeted at intracellular delivery of biological molecules, drugs and therapeutics for the treatment and prevention of metabolic diseases, diabetes, obesity, dyslipidemia, fibrotic diseases, liver disease, lung disease, kidney fibrosis, rare diseases, orphan diseases, cancer, genetic diseases, autoimmune diseases, neurological diseases, infectious diseases, cardiovascular diseases, neoplastic diseases, respiratory diseases, endocrine diseases, inflammatory diseases, musculoskeletal disorders, gastrointestinal and hepatic diseases, renal and urological diseases, reproductive diseases, gynecological disorders, dermatological diseases, ophthalmic diseases, hematological disorders, or diseases affecting the organs; diagnostic preparations for medical purposes; Biological preparations for use in cell cultures for medical and veterinary purposes; nutrients for cell cultures being nutrient preparations sold as a component ingredient of for cultivating drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; living cells for medical use; genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules to target cells, for use as pharmaceutical and drug delivery agents | ACTIVE | — |
| 042 | Scientific and technological services, namely scientific and medical research and new product design services in the fields of biology, medicine, pharmaceuticals, drug delivery, biotechnology, gene editing, drug discovery, and vaccines; medical research laboratory services, pharmaceutical research and development relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; Conducting clinical trials for others relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; drug discovery services relating to the targeted intracellular delivery of biological molecules, drugs, and therapeutics; pharmaceutical laboratory research services relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; Medical research services in the fields of metabolic diseases, diabetes, obesity, dyslipidemia, fibrotic diseases, liver disease, lung disease, kidney fibrosis, rare diseases, orphan diseases, cancer, genetic diseases, autoimmune diseases, neurological diseases, infectious diseases, cardiovascular diseases, neoplastic diseases, respiratory diseases, endocrine diseases, inflammatory diseases, musculoskeletal disorders, gastrointestinal and hepatic diseases, renal and urological diseases, reproductive diseases, gynecological disorders, dermatological diseases, ophthalmic diseases, hematological disorders, or diseases affecting the organs relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; Scientific research in the field of pharmacy relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; Research and development of vaccines relating to the targeted intracellular delivery of biological molecules, drugs, and therapeutics; Scientific investigations for medical purposes relating to the targeted intracellular delivery of biological molecules, drugs, and therapeutics; development of pharmaceutical preparations and medicines; pharmaceutical drug development services for the targeted intracellular delivery of biological molecules, drugs and therapeutics; medical research laboratory services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics, and in the field of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; research and development in the fields of gene editing and drug delivery relating to the targeted intracellular delivery of biological molecules, drugs and therapeutics; scientific and technological services and research and design, and biotechnological research services, drug discovery services, clinical trials, laboratory research services, medical research, pharmaceutical drug development services, pharmaceutical research and development, all relating to genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; research and development of vaccines and medicines relating to, and in the field of drug delivery relating to, genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; information, advisory and consultancy services relating to all of the aforesaid | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 14, 2026 | CNTA | APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER | — |
| Oct 14, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 14, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 14, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 14, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 26, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 26, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 26, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 14, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 14, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 14, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 13, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 13, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 13, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 9, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 8, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 10, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 10, 2026 | NWAP | NEW APPLICATION ENTERED | — |